Currentculinary health fundPolicy N/A

Dermatology - Ycanth Utilization Management Medical Policy

This policy governs prior authorization and medical benefit coverage criteria for Ycanth topical solution for treatment of molluscum contagiosum in patients aged 2 years and older for Culinary Health Fund members and treating providers.

Policy Summary

Payerculinary health fund

PolicyDermatology - Ycanth Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateFeb 18, 2026

Key ActionObtain prior authorization and approve Ycanth for 3 months when the patient meets the authorization criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥2minimum patient age for indication

3 monthsinitial approval duration

up to 2approved applicators per treatment

21 daysminimum interval between treatments

PAauthorization recommendation

Recommended Authorization Criteria

Policy Summary

Payerculinary health fund

PolicyDermatology - Ycanth Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateFeb 18, 2026

Key ActionObtain prior authorization and approve Ycanth for 3 months when the patient meets the authorization criteria.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indication

Approve Ycanth for 3 months if the patient meets ALL of the following (A, B, and C):

Operational note: Initial approval duration: 3 months

Dosing

Dosing limits when approved:

Dosing: Approve up to two applicators per treatment, not more frequently than once every 21 days

Coverage of Ycanth is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. Requests that fall outside the specified criteria may be denied; the criteria will be updated as new published data become available.

Prior Authorization & Documentation Requirements

Prior Authorization

Prior authorization required for Ycanth

Prior Authorization is recommended for medical benefit coverage of Ycanth. When the patient meets the Recommended Authorization Criteria and Dosing, approve for 3 months (1 month = 30 days).

Approvals are provided for the duration noted (3 months when criteria met).
Extended approvals allowed if patient continues to meet Criteria and Dosing.

Step Therapy

Dose exceptions reviewed case‑by‑case

Requests for doses outside the established dosing in this policy will be reviewed on a case‑by‑case basis by a clinician (Medical Director or Pharmacist).

Dosing when approved: up to two applicators per treatment, not more frequently than once every 21 days (exceptions require clinician review).

Documentation Required

Required documentation for prior authorization

Prior Authorization requests should include documentation that demonstrates the patient is ≥ 2 years of age, that Ycanth is being administered by a healthcare professional, and whether lesions are new or previously treated (including prior Ycanth treatment cycles if applicable).

Patient age (≥ 2 years).
Evidence Ycanth will be/was administered by a healthcare professional.
Whether lesions are new or previously treated and number of prior Ycanth treatment cycles if applicable.

Denial Risk

Non‑listed indications may be denied

Coverage is not recommended for indications or circumstances that are not listed in the Recommended Authorization Criteria; requests outside those criteria may be denied.

Criteria will be updated as new published data become available.

Clinical Background

Molluscum contagiosum is a common viral skin infection from the Poxviridae family that produces small, dome-shaped papules which may be white, pink, or flesh-colored and commonly appear on the trunk, face, and extremities. The condition is most often seen in children, can be spread by direct contact, and may cause pruritus, pain, eczematous changes, or secondary bacterial infection.

The natural history is typically self-limited: many lesions resolve spontaneously within 6–12 months, though some cases persist longer and disease can be more extensive in patients with atopic dermatitis or immunocompromise. Ycanth (cantharidin 0.7% topical) is indicated for treatment in patients aged ≥ 2 years and is intended to be applied by a healthcare professional as part of management for molluscum contagiosum.

Key Definitions

inv-09: Molluscum contagiosum — Definition and typical clinical presentation.

DefinitionMolluscum contagiosum: a viral skin infection of the Poxviridae family producing white, pink, or flesh-colored bumps that may occur alone or in groups and is spread by direct contact.

Common locationsTrunk, face, and extremities.

Typical symptomsMay cause pain, itching, eczema, and secondary bacterial infections.

Natural historyOften resolves within 6–12 months but can persist longer in some cases.

Risk modifiersMore common in children; more extensive or persistent disease in patients with atopic dermatitis or immunocompromise.

inv-10: Ycanth — Cantharidin 0.7% topical solution indication summary.

Active ingredient and strengthCantharidin 0.7% topical solution (Ycanth).

IndicationTreatment of molluscum contagiosum in patients 2 years of age and older.

Provider administrationMust be administered by a healthcare professional (per coverage criteria requirements).

Authorization notePrior Authorization is recommended for medical benefit coverage; approve for 3 months when criteria are met.